Tech Company Financing Transactions
Impact Biomedicines Funding Round
Oberland Capital joined a $90 million funding round for Impact Biomedicines. The funding round was announced on 10/27/2017.
Transaction Overview
Company Name
Announced On
10/27/2017
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Undisclosed
Investors
Oberland Capital (Andrew Rubinstein)
Proceeds Purpose
This financing with Oberland Capital paves the way with the financial resources we need to pursue our plans.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12526 High Bluff Dr. 260
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Impact Biomedicines is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Hood
Chief Financial Officer
Raghu Saripalli
Chief Medical Officer
Catriona Jamieson
President
Charles McDermott
Vice President
Randy Adams
VP - Operations
Jeffery Barker
Browse more venture capital transactions:
Prev: 10/27/2017: PropelPLM venture capital transaction
Next: 10/27/2017: Blue Canoe Learning venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs